Kobe University, Knc Laboratories Co.,Ltd., and Dainippon Sumitomo Pharma Co., Ltd. announced the signing of an exclusive world wide license agreement for the development, manufacturing and sales of promising compounds co-discovered by Kobe University and KNC, that are related to the Ras signaling pathway. According to the terms of the agreement, Dainippon Sumitomo Pharma will make an upfront payment and thereafter milestone and royalty payments to Kobe University and Knc Laboratories. In addition, Dainippon Sumitomo Pharma and Kobe University have signed a joint research agreement aiming at the discovery of anti-cancer drugs, beyond the scope of the license agreement, that are relevant to the Ras-dependent signal transduction.